Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0VHRBL
ADC Name
RC-88
Synonyms
RC 88; RC-88; RC-88 ADC; RC88
   Click to Show/Hide
Organization
RemeGen Co., Ltd.
Drug Status
Phase 1/2
Indication
In total 9 Indication(s)
Breast cancer
Phase 2
Clinical Trial
Fallopian tube cancer
Phase 2
Clinical Trial
Gastric cancer
Phase 2
Clinical Trial
Lung cancer
Phase 2
Clinical Trial
Ovarian cancer
Phase 2
Clinical Trial
Pancreatic cancer
Phase 2
Clinical Trial
Peritoneal cancer
Phase 2
Clinical Trial
Pleura mesothelioma
Phase 2
Clinical Trial
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Misitatug
  Antibody Info 
Antigen Name
Mesothelin (MSLN)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random Cysteines
Combination Type
vedotin
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT04175847
Phase 1/2
To evaluate the safety of RC88 for injection in patients with advanced malignant solid tumors, multicenter, open, multi-cohort extension of efficacy and pharmacokinetic characteristics phase 1 /2a clinical study.

   Click to Show/Hide
Undisclosed  NCT04175847
Phase 1/2
To evaluate the safety of RC88 for injection in patients with advanced malignant solid tumors, multicenter, open, multi-cohort extension of efficacy and pharmacokinetic characteristics phase 1 /2a clinical study.

   Click to Show/Hide
Undisclosed  NCT05508334
Phase 1
An open-label, non-randomised, multicentre study to allow continued access to and assess the safety and tolerability of RC88 for patients with advanced solid tumours.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT04175847  Clinical Status Phase 1/2
Clinical Description To evaluate the safety of RC88 for injection in patients with advanced malignant solid tumors, multicenter, open, multi-cohort extension of efficacy and pharmacokinetic characteristics phase 1 /2a clinical study.
Experiment 2 Reporting the Activity Date of This ADC [2]
Patients Enrolled
Patients with malignant pleural mesothelioma and MSLN in advanced malignant solid tumors.
Administration Dosage
Dose of 0.10, 0.50, 1.00, 1.50, 2.00 and 2.50 mg/kg.
Related Clinical Trial
NCT Number NCT04175847  Clinical Status Phase 1/2
Clinical Description To evaluate the safety of RC88 for injection in patients with advanced malignant solid tumors, multicenter, open, multi-cohort extension of efficacy and pharmacokinetic characteristics phase 1 /2a clinical study.
Experiment 3 Reporting the Activity Date of This ADC [3]
Related Clinical Trial
NCT Number NCT05508334  Clinical Status Phase 1
Clinical Description An open-label, non-randomised, multicentre study to allow continued access to and assess the safety and tolerability of RC88 for patients with advanced solid tumours.
References
Ref 1 To Evaluate the Safety of RC88 for Injection in Patients With Advanced Malignant Solid Tumors,Multicenter, Open, Multi-cohort Extension of Efficacy and Pharmacokinetic Characteristics Phase I /IIa Clinical Study, NCT04175847
Ref 2 A new immunochemical strategy for triple-negative breast cancer therapy. Sci Rep. 2021 Jul 21;11(1):14875.
Ref 3 An Open-label, Non-randomised, Multicentre Study to Allow Continued Access to and Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours, NCT05508334